Figg WD - Search Results

1

A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.

Figg WD, Monga M, Headlee D, Shah A, Chau CH, Peer C, Messman R, Elsayed YA, Murgo AJ, Melillo G, Ryan QC, Kalnitskiy M, Senderowicz AM, Hollingshead M, Arbuck SG, Sausville EA. Figg WD, et al. Cancer Chemother Pharmacol. 2014 Nov;74(5):955-67. doi: 10.1007/s00280-014-2569-7. Epub 2014 Sep 3. Cancer Chemother Pharmacol. 2014. PMID: 25183650 Free PMC article. Clinical Trial.

2

A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer.

Figg WD, Thibault A, Cooper MR, Reid R, Headlee D, Dawson N, Kohler DR, Reed E, Sartor O. Figg WD, et al. Cancer. 1995 Apr 15;75(8):2159-64. doi: 10.1002/1097-0142(19950415)75:8<2159::aid-cncr2820750820>3.0.co;2-o. Cancer. 1995. PMID: 7535186 Clinical Trial.

3

Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine.

Piscitelli SC, Thibault A, Figg WD, Tompkins A, Headlee D, Lieberman R, Samid D, Myers CE. Piscitelli SC, et al. Among authors: figg wd. J Clin Pharmacol. 1995 Apr;35(4):368-73. doi: 10.1002/j.1552-4604.1995.tb04075.x. J Clin Pharmacol. 1995. PMID: 7650225 Clinical Trial.

4

Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.

Bitton RJ, Figg WD, Venzon DJ, Dalakas MC, Bowden C, Headlee D, Reed E, Myers CE, Cooper MR. Bitton RJ, et al. Among authors: figg wd. J Clin Oncol. 1995 Sep;13(9):2223-9. doi: 10.1200/JCO.1995.13.9.2223. J Clin Oncol. 1995. PMID: 7666080 Clinical Trial.

5

Phase I study of phenylacetate administered twice daily to patients with cancer.

Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, Headlee DJ, Kohler DR, Venzon DJ, Myers CE. Thibault A, et al. Among authors: figg wd. Cancer. 1995 Jun 15;75(12):2932-8. doi: 10.1002/1097-0142(19950615)75:12<2932::aid-cncr2820751221>3.0.co;2-p. Cancer. 1995. PMID: 7773944 Clinical Trial.

6

Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study.

Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES, Solomon D, Figg WD, Herdt J, Kopp WC, Rager H, Steinberg SM, et al. Sausville EA, et al. Among authors: figg wd. Blood. 1995 Jun 15;85(12):3457-65. Blood. 1995. PMID: 7780133 Free article. Clinical Trial.

7

Acute renal toxicity associated with suramin in the treatment of prostate cancer.

Figg WD, Cooper MR, Thibault A, Headlee D, Humphrey J, Bergan RC, Reed E, Sartor O. Figg WD, et al. Cancer. 1994 Sep 1;74(5):1612-4. doi: 10.1002/1097-0142(19940901)74:5<1612::aid-cncr2820740519>3.0.co;2-q. Cancer. 1994. PMID: 8062193

8

A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.

Thibault A, Cooper MR, Figg WD, Venzon DJ, Sartor AO, Tompkins AC, Weinberger MS, Headlee DJ, McCall NA, Samid D, et al. Thibault A, et al. Among authors: figg wd. Cancer Res. 1994 Apr 1;54(7):1690-4. Cancer Res. 1994. PMID: 8137283 Clinical Trial.

9

Hypothyroidism associated with aminoglutethimide in patients with prostate cancer.

Figg WD, Thibault A, Sartor AO, Mays D, Headlee D, Calis KA, Cooper MR. Figg WD, et al. Arch Intern Med. 1994 May 9;154(9):1023-5. Arch Intern Med. 1994. PMID: 8179445

10

Anaphylactoid reaction with suramin.

Thibault A, Figg WD, Cooper MR, Prindiville SA, Sartor AO, Headlee DJ, Myers CE. Thibault A, et al. Among authors: figg wd. Pharmacotherapy. 1993 Nov-Dec;13(6):656-7. Pharmacotherapy. 1993. PMID: 8302692

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

793 results

Search Page

Filters